Autoimmune Disease Series: Will Biologics Emerge as New Treatments for Reactive Arthritis?

Autoimmune Disease Series: Will Biologics Emerge as New Treatments for Reactive Arthritis? published by Decision Resources, Inc. in December, 2008. This report consists of 26 Pages and the price starts from US $ 6750.

Introduction

Abstract

“Despite the strong position biologic therapies have claimed in other infl ammatory diseases, these agents have not established themselves as a common treatment for ReA. Only clinical data supporting their effi cacy over the popular NSAIDs and DMARDs are likely to move biologics out of their position as a last-line therapy. However, the small patient population for ReA makes it unlikely that drug companies will see a signifi cant return from expensive clinical trials, making this strategy impractical. Biologic manufacturers would be best served by focusing on other spondyloarthropathies or infl ammatory diseases, and use the momentum from those markets to drive some sales in ReA.” - Jennifer Moniz Carpenter, M.B.A., Program Manager

Introduction

Reactive arthritis (ReA), a seronegative spondyloarthropathy that is believed to be partially autoimmune and triggered by the presence of a bacterial infection, is rare. For that reason, along with the availability of generic agents and the relatively benign nature of the disease, the market for reactive arthritis therapies is limited. Nonetheless, the treatment of chronic and refractory reactive arthritis remains a target for drug development. How promising a target? To answer that question, Decision Resources surveyed specialists to uncover their treatment choices for reactive arthritis and to determine whether any emerging therapy will cause a signifi cant change in the market.

• Reactive arthritis is an infl ammatory disease triggered by a bacterial infection, " usually gastrointestinal or urogenital in origin.What are the symptoms of reactive arthritis? How is the disease diagnosed? What are the drugs commonly used to treat reactive arthritis?
• Reactive arthritis is a rare disease that occasionally goes into spontaneous remission. How many individuals in the United States are diagnosed with reactive arthritis? How will the diagnosed population grow over the next ten years?
• Reactive arthritis mainly affects the joints, with chronic disease sometimes becoming debilitating. What are specialists' choices for fi rst-line therapies to treat reactive arthritis? Are there any agents in development for ReA? What role will biologic therapies play in the treatment of ReA?

Scope

• Overview of reactive arthritis: disease defi nition, pathogenesis, symptoms, diagnosis
• Epidemiology: Diagnosed U.S. cases of reactive arthritis, 2007-2012
• Current therapies: Surveyed specialists' therapy choices, NSAIDs, DMARDs
• Use of biologics in the treatment of reactive arthritis: TNF-α inhibitors, emerging biologic therapies
• Outlook for reactive arthritis market: 2007 sales, outlook for emerging therapies
• This report is part of the Autoimmune Disease Series: In 2007, sales of agents used to treat autoimmune disorders exceeded $20 billion. Still, for many of the more than 80 identified autoimmune disorders, treatment options are limited. Targeting underserved autoimmune diseases offers drug developers the opportunity to introduce their agents into the autoimmune market while taking advantage of the minimal competition and an expedited regulatory process. The Autoimmune Disease Series provides critical market information, including disease prevalence, profi les of marketed and emerging agents, and insight into the prescribing choices of disease specialists.

• Companies
• Abbott
• Amgen
• Astellas
• AstraZeneca
• Biogen Idec
• Bristol-Myers Squibb
• Centocor
• Chugai
• Dava Pharmaceuticals
• Eisai
• Genentech
• Janssen
• Medarex
• Mitsubishi Tanabe
• Novartis
• Ovation
• Pfi zer
• Procter & Gamble
• Roche
• Schering-Plough
• Takeda
• UCB
• Wyeth

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Overview of Reactive Arthritis
  • Disease Description and Etiology
  • Clinical Manifestations
    • Joint Symptoms
    • Eye Symptoms
    • Skin Symptoms
• Epidemiology
  • Overview
  • Disease Defi nition
  • Methods
• Current Therapies for Reactive Arthritis
  • NSAIDs
  • Conventional Disease-Modifying Antirheumatic Drugs
• The Use of Biologics in Reactive Arthritis
  • Current Role of Biologic Therapy
  • Emerging Biologic Therapies
    • Centocor/Schering-Plough/Janssen/Mitsubishi Tanabe' s Golimumab
    • Biogen Idec/Genentech/Roche' s Ocrelizumab
    • Interleukin-Based Therapies
• Outlook for the Reactive Arthritis Market
• Bibliography

Tables

• 1. Agents Used in the Treatment of Reactive Arthritis
• 2. Approved TNF-ƒ¿ Inhibitors, 2008
• 3. Emerging Biologic Agents, 2008

Figures:

• 1. Specialist' s Estimates of Reactive Arthritis Symptom Frequency
• 2. Prevalent Cases of Reactive Arthritis in the United States, 2007-2017
• 3. Survey Question: Please indicate your fi rst-line therapy choice for reactive arthritis
• 4. Survey Question: Please indicate your second-line therapy choice for reactive arthritis
• 5. Survey Question: Please indicate your third-line therapy choice for reactive arthritis
• 6. Survey Question: How many of your patients will require new or additional therapy within the following time frames?
• 7. Survey Question: What percentage of your reactive arthritis patients receive the following biologic therapies? .
• 8. Survey Question: Would you prescribe golimumab to your reactive arthritis patients?
• 9. Survey Question: Would you prescribe tocilizumab to your reactive arthritis patients?
• 10. Survey Question: What agents are most likely to be replaced by golimumab?
• 11. Survey Question: What agents are most likely to be replaced by tocilizumab?

Related Reports